“We envisaged that blood test-based screening will allow better use of health resources by identifying the right patients for endoscopy while reducing unnecessary procedures,” Michelle Hill, head of QIMR Berghofer’s Precision and Systems Biomedicine Laboratory, said in a statement. “Most importantly, once found, the pre-cancerous cells and early-stage esophageal adenocarcinoma can be effectively treated, thereby improving survival from this deadly cancer.“
Article: QIMR Berghofer Licenses Esophageal Cancer Blood Biomarkers to Proteomics International